Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 6;387(14):1329-1331.
doi: 10.1056/NEJMc2210546. Epub 2022 Sep 7.

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants

Panke Qu  1 , Julia N Faraone  1 , John P Evans  1 , Yi-Min Zheng  1 , Lianbo Yu  1 , Qin Ma  1 , Claire Carlin  1 , Gerard Lozanski  1 , Linda J Saif  1 , Eugene M Oltz  1 , Richard J Gumina  1 , Shan-Lu Liu  1
Affiliations

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants

Panke Qu et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Durability of mRNA Booster–Induced Neutralizing Antibodies According to Previous SARS-CoV-2 Infection.
Panel A shows neutralizing-antibody titers against virus pseudotyped with spike protein from the ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the D614G mutation and the B.1.1.529 (omicron) subvariants BA.1, BA.2.12.1, and BA.4 and BA.5 (hereafter, BA.4/5) in serum samples obtained from health care workers with no previous SARS-CoV-2 infection. Samples were obtained from participants who had received a booster dose of messenger RNA (mRNA) vaccine 1 to 3 months, 4 to 6 months, or 7 to 9 months previously. Neutralizing-antibody titers against virus with the D614G mutation and the omicron subvariants BA.1, BA.2.12.1, and BA.4/5 in serum samples obtained from participants with previous SARS-CoV-2 infection are shown in Panel B; samples were obtained according to the same time categories as in Panel A. In both panels, dots represent individual samples, and the horizontal dashed lines represent the limit of detection. Solid lines connect samples that were obtained from the same participant. Geometric mean values for the 50% neutralization titers (NT50) are shown at the top of the plots for each time point. Panel C shows the trend lines in neutralizing-antibody decay over the study period as determined by linear mixed-effects modeling with accounting for repeated measures in participants with no previous SARS-CoV-2 infection against virus with the D614G mutation (slope, −0.0028; 95% CI, −0.0037 to −0.0018) or subvariants BA.1 (slope, −0.0031; 95% CI, −0.0048 to −0.0015), BA.2.12.1 (slope, −0.0030; 95% CI, −0.0045 to −0.0014), or BA.4/5 (slope, −0.0032; 95% CI, −0.0047 to −0.0016) and in participants with previous SARS-CoV-2 infection against virus with the D614G mutation (slope, −0.0027; 95% CI, −0.0050 to −0.0004) or subvariants BA.1 (slope, −0.0022; 95% CI, −0.0054 to −0.0010), BA.2.12.1 (slope, −0.0015; 95% CI, −0.0047 to −0.0016), or BA.4/5 (slope, −0.0019; 95% CI, −0.0047 to −0.0010). The 95% confidence intervals for each trend-line slope have not been adjusted for multiplicity and should not be used in place of hypothesis testing.
See this image and copyright information in PMC

References

    1. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:255-263. - PMC - PubMed
    1. Qu P, Faraone J, Evans JP, et al. Neutralization of the SARS-CoV-2 omicron BA.4/5 and BA.2.12.1 subvariants. N Engl J Med 2022;386:2526-2528. - PMC - PubMed
    1. Evans JP, Zeng C, Carlin C, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med 2022;14:eabn8057-eabn8057. - PMC - PubMed
    1. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun 2022;13:3082-3082. - PMC - PubMed
    1. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA 2021;326:1930-1939. - PMC - PubMed

Publication types

Supplementary concepts